RxDoctor Payments Data

Francis Long, MD

Otolaryngology · Sheffield, ALNPI 1790985133

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (44.2%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. Optinose US, Inc. accounts for 65.4% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2019 at $4,790 and has fallen 92.2% since, to $376 in 2025.

$6,788in general payments, 2019–2025

Across 56 payments — averaging $121.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Optinose US, Inc.$4K
  • Inspire Medical Systems, Inc.$1K
  • Stryker$476
  • Intersect ENT, Inc.$134
  • Regeneron Healthcare Solutions, Inc.$93
  • GSK$67
  • plus $155 from 6 others

What the payments were for

  • Consulting fees$3,00044%
  • Travel & lodging$2,32134%
  • Food & beverage$1,46822%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,788 in reported general payments places this provider in the 85th percentile of 155 otolaryngology providers in Alabama.

See all otolaryngology providers in Alabama

Medicare billing

Part B allowed, 2024
$183,704
Medicare patients
624
Services billed
5,355

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Fluticasone Propionate436$6,324
Esomeprazole Magnesium91$5,809
Levocetirizine Dihydrochloride452$4,394
Desloratadine80$3,267
Ipratropium Bromide88$3,209
Epinephrine12$2,723
Cefprozil76$2,693
Fluocinolone Acetonide Oil51$2,570
Azelastine Hcl81$2,264
Cimetidine62$2,077
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav130$1,373
Ofloxacin34$1,269
Montelukast Sodium128$1,097
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha70$1,042
Methylprednisolone112$910

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Hikma Pharmaceuticals USAEpinephrine$16$2,72312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 155 otolaryngology providers in Alabama.

Other otolaryngology in Sheffield

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →